Epsilogen Acquires TigaTx, Advancing Cancer Antibody Innovation
Deal News | Apr 07, 2025 | ALSA Ventures
Epsilogen, a leader in immunoglobulin E (IgE) antibody therapeutics, announces its acquisition of TigaTx, a biotechnology firm specializing in immunoglobulin A (IgA) antibodies. The move positions Epsilogen as the world's leading pan-isotype cancer antibody company, enabling the incorporation of IgA and IgE capabilities into a unified strategy for cancer treatment. This merger is aimed at optimizing the therapeutic potential of different antibody isotypes for targeted cancer therapy. The clinical-stage company plans to leverage IgA's activation of neutrophils and IgE's activation of T cells and macrophages into innovative hybrid antibody molecules with enhanced efficacy. Epsilogen's pipeline, bolstered by the acquisition, includes MOv18 IgE, an antibody in trials for platinum-resistant ovarian cancer, and EPS 401 (formerly TIGA-001), entering clinical study phases. The financial terms of the acquisition remain undisclosed. Notable board changes include the addition of Dr. Sonia Gulati from Global BioAccess Fund.
Sectors
- Biotechnology
- Healthcare
Geography
- United Kingdom – Epsilogen is based in London, making the UK a relevant geography for the transaction discussed in the article.
- United States – TigaTx, the acquired company, is based in Boston, MA, contributing to the relevance of the U.S. in the merger.
Industry
- Biotechnology – The article discusses the acquisition of TigaTx by Epsilogen, both companies being involved in biotechnology development, specifically focusing on engineered antibodies for cancer treatment.
- Healthcare – The focus on cancer antibody therapeutics places the article within the healthcare sector as it concerns advancements in medical treatments for cancer.
Financials
- Not Disclosed – The financial terms of the acquisition between Epsilogen and TigaTx have not been publicly disclosed.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Epsilogen Ltd | Bidding Company | Company | Epsilogen is a UK-based company specializing in the development of pan-isotype antibody therapeutics for cancer, combining expertise in IgE, IgA, and IgG antibodies. |
| TigaTx, Inc. | Target Company | Company | TigaTx is a Boston-based biotechnology company developing engineered IgA antibodies for cancer treatment, now a wholly owned subsidiary of Epsilogen. |
| ALSA Ventures | Private Equity Firm | Company | ALSA Ventures is a venture capital firm backing promising biotech companies, such as Epsilogen in its acquisition strategy. |
| Sonia Gulati | Board Member | Person | Dr. Sonia Gulati is a Principal at Global BioAccess Fund who has joined Epsilogen's board post-acquisition. |
| Global BioAccess Fund | Investor | Company | An investment fund involved in biotech investments, represented by Dr. Sonia Gulati on Epsilogen's board. |
| Tim Wilson | CEO | Person | CEO of Epsilogen, providing strategic direction in the acquisition of TigaTx. |
| Pete Finan | Non-Executive Chairman | Person | Non-Executive Chairman of Epsilogen and General Partner at Epidarex Capital, providing insights on the acquisition's strategic benefits. |